GPs’ perceptions of their relationship with the pharmaceutical industry: a qualitative study

James Larkin, MSc1*, Ivana Pericin, MSc2, Maurice Collins, MSc1, Susan M Smith, MD1, David Byrne, MB, BCh, BAO1, Frank Moriarty, PhD3

1Department of General Practice, RCSI University of Medicine and Health Sciences, Dublin, Ireland; 2School of Social Work and Social Policy, Trinity College Dublin, Dublin, Ireland; 3School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, Dublin, Ireland

Abstract

Background: The pharmaceutical industry invests heavily in promoting medications to physicians. This promotion may influence physicians’ prescribing behaviour and lead to inappropriately increased prescribing rates.

Aim: To understand GPs’ experience of interacting with the pharmaceutical industry, and explore their views and perceptions of the impact of this interaction in general practice in Ireland.

Design & setting: A qualitative design was used, and GPs practicing in Ireland were eligible.

Method: A combination of purposive and snowball sampling techniques was applied and semi-structured interviews were conducted. Thematic analysis was used to develop themes from the data.

Results: Twenty-one GPs and one GP trainee participated. Five themes were developed: 1) GP and pharmaceutical industry interface; 2) the industry’s methods of influence; 3) the uncomfortable relationship between GPs and industry; 4) GPs’ perceptions of being unconsciously influenced; and 5) GPs’ lack of knowledge of relevant regulations.

Participants interacted with pharmaceutical representatives in their surgery and through continuing professional development (CPD). Reported methods of influence included biased information and the offer of gifts. Most participants felt their prescribing was unconsciously influenced. A minority felt that they were only influenced in a way that improved their prescribing.

Conclusion: The study shows that there can be a lack of clarity among GPs about relevant regulations and about the potential impact on prescribing of interactions with the pharmaceutical industry. Education of trainees and GPs has the potential to address this. Restrictions on interactions with the pharmaceutical industry may also play a role, although alternative CPD funding sources would need to be established.

How this fits in

Previous research shows that physician interactions with the pharmaceutical industry can influence prescribing behaviour, and lead to inappropriately increased prescribing rates and lower prescribing quality. This qualitative study of GPs shows that the pharmaceutical industry is interacting with and influencing GPs in numerous ways. Understanding these interactions and GPs’ perceptions of them can inform strategies to ensure an appropriate relationship between GPs and the pharmaceutical industry.
Introduction

Pharmaceutical companies spend large amounts of money on promotion of medications, with most activities directed at physicians.1,2 Physicians’ prescribing decisions are directly influenced by the promotion of medication.3-6 However, information communicated by pharmaceutical representatives is often inaccurate,7-9 and physicians often underestimate the impact of these promotional activities on their prescribing behaviours.8 A 2017 systematic review reported a ‘consistent association’ between physician interactions with the pharmaceutical industry and ‘inappropriately increased prescribing rates, lower prescribing quality, and/or increased prescription costs’.3 Inappropriate prescribing has the potential to harm patients, increase costs, and impair public trust in health care.

GPs are an important promotional target for the pharmaceutical industry because they initiate a high proportion of patient prescriptions.10,11 US evidence showed that 15% of physicians in receipt of pharmaceutical industry payments were family physicians.12 Previous studies have examined GPs’ interactions with the pharmaceutical industry in Ireland and found that pharmaceutical representatives were one of GPs’ primary sources for information on new drugs.13,14 However, these studies predate the 2007 regulation on the promotion of medicinal products,15 as well as the Medical Council guidance and updated Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice,16 all described below. A 2016 meta-synthesis on interactions between pharmaceutical representatives and physicians found few studies conducted with GPs.17 Moreover, the majority of studies included in this meta-synthesis were conducted >10 years ago.17 A recent qualitative study conducted across three countries found that primary care physicians considered pharmaceutical representatives to be biased, but believed that they themselves were immune from representatives’ influence.18

Interactions between the pharmaceutical industry and physicians are an area of public interest.19,20 In Ireland, these interactions are regulated by the Medical Council and a 2007 regulation.15,21 The Medical Council guidance is detailed, but most notably states that physicians should not accept gifts or hospitality.21 The 2007 regulation19 includes requirements for accuracy of advertising, and considers pharmaceutical representative visits within the definition of advertising. The regulation15 also states that free samples should be provided to prescribers on an exceptional basis only, that gifts should be inexpensive and relevant to the practice of medicine, and that reasonable hospitality is only allowed at professional or scientific events. UK regulations make similar provisions.22 The pharmaceutical industry has a code of practice for interacting with healthcare professionals. It was developed by the IPHA,16 which represents the international biopharmaceutical industry, and is based on the 2019 European Federation of Pharmaceutical Industries and Associations Code of Practice.23

Overall, the pharmaceutical industry is dynamic in its response to the regulatory environment,24 creating a need for up-to-date research. Also, Ireland offers an interesting case, as the regulatory environment, which has changed in recent years, is similar to many European countries. This research, therefore, aims to understand the experience of GPs in Ireland when interacting with the pharmaceutical industry, and to explore their views and perceptions of the pharmaceutical industry’s involvement with general practice and potential impact on prescribing.

Method

Study design and setting

This qualitative study is reported according to the COREQ guidelines.25 A phenomenological approach was applied to gather rich, in-depth data and gain a better understanding of GPs’ perceptions and everyday experiences. Semi-structured interviews were employed to facilitate the collection of in-depth information. The interview topic guide (see Supplementary Appendix A) was developed by two GPs (SS, DB), a pharmacist (FM), and two social scientists (JL, IP). The topic guide was not piloted. The main topics were:

- ‘Exploring contact’;
- ‘Meetings and information’;
- ‘Other interactions’;
- ‘Regulation’; and
- ‘Prescribing decisions’.

The interviews took place between July and September 2020.
Participants
A combination of purposive and snowball sampling was used to recruit GPs. To increase generalisability and minimise bias, the researchers selected GPs from a mix of geographic areas, with a diverse length of time practicing, and who were of both male and female sex. Participants were recruited through the authors’ professional contacts, or suggestions from participants. In instances where there was a pre-existing relationship between researcher and participant, a researcher with no relationship to the participant conducted the interview. Invitations to participate were sent by email. Participants were provided with an information sheet and consent form before participation. Four people did not reply to requests for participation.

Data collection
Semi-structured interviews were conducted via either telephone or the Zoom platform. Telephone interviews are useful in mitigating the complexity in accessing health professionals, and are considered appropriate for semi-structured interviews. Furthermore, the Zoom platform was found to be cost-effective and satisfactory by researchers and participants. Interviews were conducted by one of three researchers (JL, IP, MC), and lasted 15–45 minutes. Field notes were made after interviews and discussed among interviewers. Interviews were audio-recorded and transcribed verbatim. Transcripts were pseudonymised by assigning them a unique ID, and were returned to participants to provide an opportunity for corrections. They were then anonymised.

Data analysis
Thematic analysis, following a six-step process, was employed to identify patterned meanings and common themes within and across the dataset. Firstly, the transcripts were read and re-read, to achieve data familiarisation, followed by line-by-line coding, where meaningful parts of texts were organised into codes and categories. The process was carried out by a single author (JL) who by employing an inductive approach, reviewed the codes to assess the commonality and differences between the interviews. Using the comparative analysis between and within transcripts, the author (JL) labelled codes based on the meaning and relationships between them into categories, which were synthesised into the main themes. To increase the confirmability of the findings, a second author (IP) read all transcripts and crosschecked the coding structure and themes developed. This individual approach, as opposed to two independent coders, was taken to facilitate the authors’ reflexivity; the sense-checker could challenge the assumptions of the primary coder. Two authors (JL, IP) discussed the categories, clarified meanings, and identified preliminary themes. Discrepancies were addressed through discussion. Analysis was conducted using NVivo (version 12) software.

Reflexivity
Two authors (SS, DB) are GPs with a health services research background, one (FM) is a pharmacist with a health services research background, one (MC) is a medical student with a social science background, and two authors (JL, IP) have a background in social science and health services research. Three (DB, FM, SS) authors have had interactions with the pharmaceutical industry but do not currently meet with its representatives or attend events organised by it. Two authors (SS, DB) attend national educational events, which receive unrestricted funding from the pharmaceutical industry, although the pharmaceutical industry has no role in programme selection or delivery. The pharmaceutical industry has stands with representatives at the events but SS and DB avoid engaging in discussion with representatives. Authors conducting data analysis (JL, IP) reflected on and discussed their beliefs around the subject before and during analysis.

Results
Twenty-one GPs and one GP trainee participated. Table 1 provides details of the sample. Participants’ sex and practice location closely matched national figures.

Five themes were developed based on the data:
• GP and industry interface;
• methods of influence;
• an ‘uncomfortable’ relationship;


**Table 1** Participant characteristics (n = 22)

| Participant characteristics | n (%) |
|-----------------------------|-------|
| Sex                         |       |
| Male                        | 12 (55) |
| Female                      | 10 (45) |
| Practice role               |       |
| Salaried                    | 10 (45) |
| Partner                     | 10 (45) |
| Locum                       | 1 (5)  |
| Trainee                     | 1 (5)  |
| Years qualified as GP       |       |
| Trainee                     | 1 (5)  |
| 0–4                         | 5 (23)  |
| 5–9                         | 3 (14)  |
| 10–14                       | 4 (18)  |
| 15–19                       | 2 (9)   |
| ≥20                         | 7 (32)  |
| Location of practice        |       |
| Urban                       | 11 (50) |
| Rural                       | 4 (18)  |
| Mixed                       | 7 (32)  |

• perceptions of unconscious influence; and
• GPs’ lack of knowledge of regulations.

*Figure 1* illustrates the relationships between themes.

**GP and industry interface**

Participants gave detailed accounts of their interactions with the industry. There were two primary settings for meetings: the general practice surgery and CPD events. Selected illustrative quotes are provided in *Table 2*.

**Meetings in practice**

The majority of participants said that they meet pharmaceutical representatives in their surgery, either one-on-one or in groups with several GPs attending:

‘They ask to meet with everyone, but usually they are put in a room and people see them as they have time. So sometimes it’s one-to-one and sometimes it’s in a group.’ (Participant [P]15)

Practice meetings with pharmaceutical representatives would last 5–15 minutes and varied in frequency from daily meetings to once every 3 months. In some practices, the practice nurses and/or medical students would attend.

Occasionally, pharmaceutical representatives would organise a consultant doctor to speak at a practice meeting. Seven participants chose not to meet pharmaceutical representatives in their surgery.

Two GPs believed the pharmaceutical representatives they were meeting were profiling the practice’s prescribing behaviour. They believed that pharmaceutical representatives asked ‘local pharmacists which doctor prescribes their drug’ (P20). One thought that pharmaceutical representatives were obtaining prescribing data from the company running their practice software.

**Continuing professional development**

GPs also met pharmaceutical representatives outside the practice, with some saying that they come across the pharmaceutical industry ‘everywhere’ (P7). They described the pharmaceutical industry as ‘*intrinsically linked to CPD*’ (P10) because it is very active in sponsoring and organising CPD events for GPs. The majority reported that they would encounter the pharmaceutical industry at a range of sponsored events including continuing medical education (CME) small-group meetings, conferences (for example, primary care surgical society, Irish College of General Practitioners conference, GP-trainee conference), study days, and workshops. One participant mentioned that a government minister had attended an event sponsored by the pharmaceutical industry. When sponsoring smaller events such as CME small-group meetings, a pharmaceutical representative would speak to attendees individually and/or give a brief talk about their drug at the start of
For their own events, pharmaceutical companies would hire a speaker, usually a consultant doctor or GP:

‘The consultant is hired […] by the drug company to provide the masterclass.’ (P10)

Sponsorship of non-clinical workshops also took place; one participant described a sponsored stress reduction workshop and yoga class for GPs. Three participants said that some postgraduate training bodies received sponsorship from the pharmaceutical industry.

Methods of influence
The interviews revealed a range of methods employed by the pharmaceutical industry to influence GPs. The most common methods were the provision of biased information, controlling discourse, and donation of gifts and contributions. Selected illustrative quotes are provided in Table 3.

‘Biased’ information
Ten participants said they felt that pharmaceutical representatives were biased in their provision of information. Seven more participants felt that information provided was sometimes inaccurate. GPs felt that the presentation to them is like a ‘sales pitch’, where the information favoured the interests of the pharmaceutical representatives’ company:

‘I think it was cherry-picked, I think what they told you was probably what painted their product in the best light.’ (P3)

Some interviewees indicated that the benefits of the product might be amplified, and they were ‘reluctant to trust all of the information without questioning’ (P12). Participants also reported that pharmaceutical representatives would mention that a local consultant or another GP was prescribing the drug they were promoting.

A minority of participants who discussed this issue felt that the information provided by the pharmaceutical representatives they met was accurate and comprehensive.

Controlling discourse
At events run by the pharmaceutical industry, the talk (delivered by a consultant doctor or GP) would often be on a topic related to the medicine or device the pharmaceutical industry was presenting at the event. For events run by GP groups, the pharmaceutical industry would sometimes have input on the content:

‘Sometimes at less mature CME groups I suppose, they set the agenda or seek to set the agenda and they say “we’d like to bring down a fresh-faced respiratory physician from a hospital”.’ (P1)

However, most participants said their groups would prevent this from happening:

‘We exercise complete control over content and speaker.’ (P20).

However, one participant pointed out that ‘there is invariably going to be some sort of stand or brief comment made’ (P7). Another participant, when asked why the pharmaceutical industry provided
unrestricted funding, said it was because ‘they [the pharmaceutical industry] got a general association within the minds of five or six key practices.’ (P20)

This effort to control discourse was also exercised when sponsoring CPD events, where the pharmaceutical industry would often organise stands with representatives from different companies. The interviewees alluded to feeling obligated and pressured to talk with pharmaceutical representatives, since ‘they've sponsored the meeting and it wouldn't happen if they weren't there’ (P3).

Gifts and contributions
Many participants said that pharmaceutical representatives sometimes bring food (for example, sandwiches or cakes), model devices, free samples, electronic devices (for example, phone charger cables), and/or stationery to practice meetings:

‘He would end up bringing lunch for all the practice the practice manager and the secretaries and everyone.’ (P15)

Some said many of these offerings were a thing of the past, while others disclosed that it was still happening. At CPD events, participants reported that these gifts would be offered at stands. In addition, GPs said that stands at some conferences would be raffling a dinner voucher, hamper, or ‘an iPad, for those who signed their name at the stall.’ (P14).

One participant said that they had their attendance paid for at a conference along with their food and stay at a hotel. They then described feeling pressured to prescribe the pharmaceutical representative’s drug:

‘I didn’t need this drug. And I wasn’t gonna start changing people over to it, but this rep who was quite pushy clearly had the expectation that I was going to transfer patients.’ (P1)

GPs also mentioned practices receiving funding from the pharmaceutical industry for medical equipment, research, or a first aid course.

‘Uncomfortable’ relationship

‘Uncomfortable’ about meeting pharmaceutical representatives
Most participants were uncomfortable about meeting pharmaceutical representatives in their practice. Participants adopted different approaches to managing this discomfort: nine reluctantly met pharmaceutical representatives (reluctant-meeters) and seven decided not to meet them (anti-
meeters). A minority of six GPs were positive about meeting pharmaceutical representatives (eager-meeters). Selected illustrative quotes are provided in Table 4.

Reluctant-meeters
Reluctant-meeters were GPs who met pharmaceutical representatives but would prefer not to and felt ‘uncomfortable’ about meeting them. Reluctant-meeters met pharmaceutical representatives because it was practice policy, because ‘it’s always been done’ (P18), or because they did not want to be different:

‘On a personal level, I always felt very uncomfortable seeing medical reps, the reason I probably saw them was because I didn’t want to be different or do something differently to the other GPs.’ (P12)

The perception of pharmaceutical representatives as being ‘pushy’ or ‘salespeople’ were common reasons mentioned for this discomfort and led some participants to reduce the number of meetings they had with pharmaceutical representatives. Many participants stressed that one reason for meeting pharmaceutical representatives was sympathy or courtesy, or to help them ‘keep their jobs’ (P1). Others felt they were obliged to meet them because they funded medical education.

However, the most common reason for reducing meetings was time. Participants discussed having busy workloads and that pharmaceutical representatives were a low priority.

Anti-meeters
The primary reason that anti-meeters did not meet pharmaceutical representatives was that they did not trust their information and considered meeting pharmaceutical representatives a ‘marketing exercise’. This led some to the view that it would have a negative impact on patients through over-medicalisation or by creating a conflict of interest:

‘[I don’t meet with them] because I do not believe that they have the patient’s interests at as their primary motivator, their primary motivating force is obviously drug profits, and the two are incompatible.’ (P4)

Eager-meeters
Eager-meeters felt they could learn from pharmaceutical representatives, and receive tailored information:

‘I think it’s a good platform and forum to become aware of new medications, new advances, new regulations, new guidelines, etc.’ (P6)

For some, pharmaceutical representatives were their only source of information on new drugs. Four participants mentioned how they enjoyed the interaction, and that pharmaceutical representatives built a relationship with them.

‘Uncomfortable’ about CPD funding
The majority of participants thought that it would be preferable if the pharmaceutical industry did not fund CPD as it led to bias. However, they also believed that funding was unlikely to come from elsewhere:

| Table 4 | Illustrative quotes on why GPs’ attitudes towards meetings with pharmaceutical representatives |
|---------|--------------------------------------------------------------------------------------------------|
| Topic   | Quote                                                                                                                                               |
| Reluctant-meeters | ‘I was never madly comfortable about it but then again on a personal level I often felt sorry for the individual people. So I would out of politeness meet people.’ (P19) |
| Anti-meeters   | ‘Meeting a rep one-to-one, who’s just there to sell a product, and won’t give me balanced views ... I have no time for that.’ (P11) |
| Eager-meeters  | ‘The relationship I would have had with the reps over the years would have been very valuable.’ (P13) |
‘Things that I would attend yes absolutely are sponsored [by the pharmaceutical industry] and it’s a really tricky one because I don’t know how you could hold a medical education conference of any kind without it.’ (P19)

Some described GP training schemes and CME groups who had made conscious decisions not to accept pharmaceutical industry funding. One reason for this decision was that participants felt there should not be a ‘vested interest’ involved in GPs’ education.

**Perceptions of unconscious influence**

The majority of participants who met pharmaceutical representatives felt that they were likely to be unconsciously influenced by them (see Table 5). This was often a reluctant reflection. Sometimes it was based on the view that the pharmaceutical industry would not invest as much money as they do in promotion if it did not influence GPs. Others came to this conclusion after reading research that outlined the impact.

Some participants felt that pharmaceutical representatives only influenced them in a way that improved their prescribing. A minority felt that they did not influence them at all:

‘If it happens to be sponsored by a drug rep who is offering me a post-it pad, and I need a post-it pad I’ll take it, but it certainly does not skew how I would prescribe.’ (P10)

Though many of these participants felt that pharmaceutical representatives did influence other GPs.

**Lack of knowledge of regulations**

Most participants lacked knowledge on regulations governing and relating to physicians’ interactions with the pharmaceutical industry. Instead, many described a general sense that things had gotten stricter:

‘I’m not sure what the regulations are, all I know is it seems things have definitely tightened up over the years.’ (P10)

Several participants had partial knowledge of gift regulations. They mentioned that gifts were not allowed, referencing practices of the past such as trips away or expensive hotel stays. The majority of participants felt that it was appropriate to regulate this type of interaction:

‘Probably it should be more regulated … obviously these people are trying to sell the drug that their company makes.’ (P15)

**Discussion**

**Summary**

GPs described meeting pharmaceutical representatives in several forums, including in their surgery and at CPD events (sponsored or organised by the pharmaceutical industry). During these meetings, participants reported that pharmaceutical representatives would use several methods to influence them, providing gifts (for example, stationery or food) and information that was perceived to be biased. Most participants felt uncomfortable about meeting pharmaceutical representatives. Many GPs reported feeling uncomfortable about the pharmaceutical industry funding CPD, with some

| Topic               | Quote                                                                                           |
|---------------------|-------------------------------------------------------------------------------------------------|
| Unconscious influence | ‘I would probably say that I don’t feel very influenced, but I think that is not correct. I think absolutely, you can be unconsciously influenced. There is a reason why pharma reps want to see doctors and want to talk to doctors because clearly, it is an effective way of getting people to prescribe whatever drug they are promoting.’ (P21) |
| Influence based on investment | ‘If they’re putting so much money into this then they must be getting something out of it.’ (P19) |
expressing concerns that alternative funding sources may not be available. Many participants felt that their prescribing behaviour was unconsciously influenced by pharmaceutical representatives. However, others did not believe this to be the case and felt that they were only influenced in a way that improved their prescribing. Finally, GPs seemed to lack a detailed knowledge of relevant regulations.

**Strengths and limitations**
The use of semi-structured interviews was flexible and allowed exploration of a range of areas, with the telephone and virtual platforms facilitating national representation. A further strength was the research team's broad disciplinary background.

Limitations include social desirability bias, particularly for questions about conflict of interest. Also, despite the purposive sampling approach, the use of professional contacts and supplementary snowball sampling may have resulted in a biased sample, though the participants' characteristics suggest this was not an issue. For data analysis, two independent coders would have increased reliability; however, the approach used facilitated reflexivity. Finally, data were collected in 2020, when GPs were not attending in-person CPD events or meeting pharmaceutical representatives owing to the COVID-19 pandemic, though they were asked to reflect on their normal practice.

**Comparison with existing literature**
Some responders thought that interacting with pharmaceutical representatives would improve their prescribing or not affect their prescribing ‘negatively’, while also thinking that their colleagues’ prescribing would be affected. This is despite research consistently demonstrating that interactions with the pharmaceutical industry can lead to inappropriately increased prescribing rates and lower prescribing quality. However, these findings align with evidence that many physicians believe pharmaceutical representatives do not influence their own prescribing, but do influence others’ prescribing. Similar doubts emerged among those who accepted funding for events. They considered the funding unrestricted, implying that the funder has no influence. However, research has shown that this funding may create a feeling of reciprocity among recipients towards the pharmaceutical industry. Or, as one participant pointed out, even when funding is ostensibly unrestricted, ‘there is invariably going to be some sort of stand or brief comment made’ (P7).

Many of this study’s findings aligned with the meta-synthesis examining interactions between physicians and pharmaceutical representatives. One of the areas which was not evident in the current research was the provision of costly gifts irrelevant to patient care, such as jewellery or televisions; this may be related to regulations in Ireland that now prohibit such gifts. A notable finding was pharmaceutical representatives telling GPs that local consultants or GPs were prescribing their company’s product as a way of influencing the GPs. This has been previously documented and described as the principles of authority and social validation. Evidence was found of key opinion leaders (KOLs) acting as speakers at events organised by the pharmaceutical industry or CME groups. KOLs are senior physicians co-opted by the pharmaceutical industry to form a central part of their efforts to influence physicians. Another important finding was that participants perceived information from pharmaceutical representatives as biased, a phenomenon documented in other countries, despite the IPHA code stating that promotion ‘must be accurate, balanced, fair, objective and must not mislead either directly or by implication’. The IPHA also states that claims about medicines should be based on ‘an evaluation of all the evidence’. Despite this, participants reported a clear impression that pharmaceutical representatives provided ‘cherry-picked’ information; for example, only discussing the ‘good trials’. These findings are in line with previous research. Another important finding was that participants discussed receiving hospitality and inexpensive gifts related to practice of medicine, despite Medical Council guidance stating that doctors should not receive gifts or hospitality.

**Implications for practice**
This research found little awareness among participants of regulations and guidelines pertaining to their relationship with the pharmaceutical industry. Educational bodies should consider providing more education on regulations, guidelines, and best practice surrounding interactions with the
pharmaceutical industry. Education is particularly pertinent given the belief among some that interactions with the industry either improve their prescribing or do not influence their prescribing. Education and restricting interactions between the pharmaceutical industry and trainee physicians and medical students have been shown to reduce interactions when they begin independent practice.41–44

Restricting meetings with pharmaceutical representatives, along with restricting the provision of free samples and promotional materials, has the potential to reduce the impact of pharmaceutical representatives on prescribing.45 As evidenced by this research, some CME groups and GP practices have a policy of not interacting with the pharmaceutical industry. These policies could be introduced at the individual, practice, representative body, or regulator level. These restrictions would be beneficial for ‘reluctant-meeters’, as many want to stop interactions with pharmaceutical representatives, but face barriers such as feeling that they would be perceived as ‘different’ if they stopped meeting them. In France, certain physicians cannot receive free samples or gifts (including food).46 In Sweden, pharmaceutical companies cannot make financial contributions towards conference attendance.47 Several physician organisations have ceased accepting funding from pharmaceutical companies,48,49 including The College of Psychiatrists of Ireland.50 Healthcare bodies and regulators could adopt similar approaches, matched with structures that support greater transparency, monitoring, and enforcement. However, physicians have reacted negatively to the idea of interactions with pharmaceutical representatives being regulated.48 This is a pertinent issue for ‘eager-meeters’, who must be considered in the context of any restrictions.

Regulation is necessary because this research suggests that there is a discrepancy between the standards in voluntary codes for the pharmaceutical industry and the industry’s conduct.51 The current industry code in Ireland52 has no proactive means of monitoring compliance and makes no provision for sanctions. The IPHA Code Council rely on ‘complaints’ and industry ‘referrals’, but since 2013 only 13 referrals or complaints have been investigated, of which 11 were upheld. Additionally, 84% of the IPHA Code Council is comprised of members of the pharmaceutical industry (Irish Pharmaceutical Healthcare Association, Findings of the Code Council and Appeals Board, personal communication, 2020). Finally, this code does not apply to pharmaceutical companies who are not members of the IPHA.

Restrictions may create a funding gap. This study’s findings support the call made by Alves et al7 for ‘publicly-financed, independent/non-commercial information to be integrated into health service provision.’ Previous research has shown that physicians support this.52 Study participants felt that there were no alternatives to pharmaceutical industry funding of CPD. Alternative sources of funding could include self-funding, state funding, and/or a hypothecated tax on the pharmaceutical industry.53

If funding were available, there are several potential vehicles for these unbiased information sources. The primary option is greater independent funding of conferences and CME small-groups. Another option — which has been trialled in academic evaluations — is educational outreach visits or academic detailing.54 Some argue that the harms associated with CPD funded by the pharmaceutical industry outweigh the benefits55,56 and should be foregone regardless of alternative funding availability.

In conclusion, this study shows that the pharmaceutical industry is interacting with GPs in multiple forums. During these interactions, GPs report that pharmaceutical representatives are using many of the methods of influence documented in the literature, including the use of KOLs and providing what is perceived to be biased information. Despite previous evidence to the contrary, some of the participants doubt that pharmaceutical representatives have any influence on their prescribing. There is also a lack of clarity among GPs about relevant regulations. Education of trainees and GPs has the potential to address this. Greater regulation and restrictions on interactions with the pharmaceutical industry may also play a role, although alternative funding sources for CPD would be needed.

**Funding**

No direct funding was received for this study. JL’s doctoral studies are funded by the Health Research Board of Ireland (funding reference CDA-2018-003). DB’s doctoral studies are funded by the Health Research Board of Ireland (funding reference CDA-2018-005).

**Ethical approval**

Ethical approval for this study was obtained from the Irish College of General Practitioners ethics committee (reference number: ICGP_REC_20_004).
Provenance
Freely submitted; externally peer reviewed.

References

1. Mack J. Pharma promotional spending in 2013: Professional Detailing, eDetailing, DTC Advertising, Professional Meetings, Journal Advertising. 2014; https://www.pharma-mktng.com/articles/prnn1305-article01/ (accessed 23 Aug 2021).
2. Jones RG, Ornstein C, Tigas M. We've Updated Dollars for Docs. Here's What's New. 2016; https://www.propublica.org/article/updated-dollars-for-docs-heres-whats-new (accessed 23 Aug 2021).
3. Brax H, Fadollahi R, Al-Khaled L, et al. Association between physicians’ interaction with pharmaceutical companies and their clinical practices: a systematic review and meta-analysis. PLoS One 2017; 12(4): e0175493. DOI: https://doi.org/10.1371/journal.pone.0175493.
4. Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med 2007; 4(4): e150. DOI: https://doi.org/10.1371/journal.pmed.0040150
5. Mason A. New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther 2008; 33(1): 1–10. DOI: https://doi.org/10.1111/j.1365-2710.2008.00875.x
6. Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs—the importance of who says what. Fam Pract 2003; 20(1): 61–68. DOI: https://doi.org/10.1093/fampra/20.1.61
7. Leonardo Alves T, Lexchin J, Mintzes B. Medicines information and the regulation of the promotion of pharmaceuticals. Sci Eng Ethics 2019; 25(4): 1167–1192. DOI: https://doi.org/10.1007/s11608-013-2411-7
8. Mintzes B, Lexchin J, Sutherland JM, et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France, and the United States. J Gen Intern Med 2013; 28(10): 1368–1375. DOI: https://doi.org/10.1007/s11608-013-2411-7
9. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995; 273(16): 1296–1298. DOI: https://doi.org/10.1001/jama.1995.03520400066047
10. Florentinus SR, Heerdink ER, van Dijk L, et al. Is new drug prescribing in primary care specialist induced? BMC Health Serv Res 2009; 9(1): 1–6. DOI: https://doi.org/10.1186/1472-6963-9-6
11. Fahey T, Sinclair H. Hospital initiated prescribing in the General Medical Services scheme. Ir Med J 1993; 86(4): 122–124.
12. Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between physician characteristics and payments from pharmaceuticals. J Gen Intern Med 2015; 30(1): 122–124. DOI: https://doi.org/10.1007/s11608-013-2411-7
13. Lexchin J, Mintzes B, Tandean R. The impact of disclosing financial ties in research and clinical care: a systematic review. J Health Econ 2015; 45: 1–10. DOI: https://doi.org/10.1016/j.jhealeco.2015.02.002
14. Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med 2007; 4(4): e150. DOI: https://doi.org/10.1371/journal.pmed.0040150
15. Mason A. New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther 2008; 33(1): 1–10. DOI: https://doi.org/10.1111/j.1365-2710.2008.00875.x
16. Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs—the importance of who says what. Fam Pract 2003; 20(1): 61–68. DOI: https://doi.org/10.1093/fampra/20.1.61
17. Leonardo Alves T, Lexchin J, Mintzes B. Medicines information and the regulation of the promotion of pharmaceuticals. Sci Eng Ethics 2019; 25(4): 1167–1192. DOI: https://doi.org/10.1007/s11608-013-2411-7
18. Mintzes B, Lexchin J, Sutherland JM, et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France, and the United States. J Gen Intern Med 2013; 28(10): 1368–1375. DOI: https://doi.org/10.1007/s11608-013-2411-7
19. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995; 273(16): 1296–1298. DOI: https://doi.org/10.1001/jama.1995.03520400066047
20. Florentinus SR, Heerdink ER, van Dijk L, et al. Is new drug prescribing in primary care specialist induced? BMC Health Serv Res 2009; 9(1): 1–6. DOI: https://doi.org/10.1186/1472-6963-9-6
21. Fahey T, Sinclair H. Hospital initiated prescribing in the General Medical Services scheme. Ir Med J 1993; 86(4): 122–124.
22. Inoue K, Blumenthal DM, Elashoff D, Tsugawa Y. Association between physician characteristics and payments from pharmaceuticals. J Gen Intern Med 2015; 30(1): 122–124. DOI: https://doi.org/10.1007/s11608-013-2411-7
23. Lexchin J, Mintzes B, Tandean R. The impact of disclosing financial ties in research and clinical care: a systematic review. J Health Econ 2015; 45: 1–10. DOI: https://doi.org/10.1016/j.jhealeco.2015.02.002
24. Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med 2007; 4(4): e150. DOI: https://doi.org/10.1371/journal.pmed.0040150
25. Mason A. New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther 2008; 33(1): 1–10. DOI: https://doi.org/10.1111/j.1365-2710.2008.00875.x
26. Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs—the importance of who says what. Fam Pract 2003; 20(1): 61–68. DOI: https://doi.org/10.1093/fampra/20.1.61
27. Leonardo Alves T, Lexchin J, Mintzes B. Medicines information and the regulation of the promotion of pharmaceuticals. Sci Eng Ethics 2019; 25(4): 1167–1192. DOI: https://doi.org/10.1007/s11608-013-2411-7
28. Mintzes B, Lexchin J, Sutherland JM, et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France, and the United States. J Gen Intern Med 2013; 28(10): 1368–1375. DOI: https://doi.org/10.1007/s11608-013-2411-7
29. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995; 273(16): 1296–1298. DOI: https://doi.org/10.1001/jama.1995.03520400066047
30. Florentinus SR, Heerdink ER, van Dijk L, et al. Is new drug prescribing in primary care specialist induced? BMC Health Serv Res 2009; 9(1): 1–6. DOI: https://doi.org/10.1186/1472-6963-9-6
31. Fahey T, Sinclair H. Hospital initiated prescribing in the General Medical Services scheme. Ir Med J 1993; 86(4): 122–124.
25. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007; 19(6): 349–357. DOI: https://doi.org/10.1093/intqhc/mzm042
26. Smith EM. Telephone interviewing in healthcare research: a summary of the evidence. Nurse Res 2005; 12(3): 32–41. DOI: https://doi.org/10.7748/nr.2005.12.3.32.c5946
27. Ottmann S. Qualitative interviews: a methodological discussion of the interviewer and respondent contexts. Forum Qual Soc Res 2016; 17(2). DOI: https://doi.org/10.17169/fqs-17.2.22551
28. Cachia M, Millward L. The telephone medium and semi-structured interviews: a complementary fit. Qual Res Organ Manag 2011; 6(3): 265–277. DOI: https://doi.org/10.1108/1746564111188420
29. Archibald MM, Ambagtsheer RC, Casey MG, Lawless M. Using Zoom videoconferencing for qualitative data collection: perceptions and experiences of researchers and participants. Int J Qual Methods 2019; 18: 160940691987459. DOI: https://doi.org/10.1177/1609406919874596
30. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006; 3(2): 77–101. DOI: https://doi.org/10.1191/1478088706qp063oa
31. Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qual Res Sport Exerc Health 2019; 11(4): 589–597. DOI: https://doi.org/10.1080/2159676X.2019.1628806
32. O’Dowd T, O’Kelly M, O’Kelly F. Structure of general practice in Ireland: 1982–2015. Dublin, Ireland: Irish College of General Practitioners; 2016.
33. Bergen N, Labonté R. “Everything Is Perfect, and We Have No Problems”: Detecting and Limiting Social Desirability Bias in Qualitative Research. Qual Health Res 2020; 30(5): 783–792. DOI: https://doi.org/10.1177/104973321989354
34. Fickweiler F, Fickweiler W, Urbach E. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic review. BMJ Open 2017; 7(9): e016408. DOI: https://doi.org/10.1136/bmjopen-2017-016408
35. Rutledge P, Crookes D, McKinstry B, Maxwell SR. Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? results from a questionnaire. Pharmacoepidemiol Drug Saf 2003; 12(8): 663–667. DOI: https://doi.org/10.1002/pds.884
36. Morgan MA, Dana J, Loewenstein G, et al. Interactions of doctors with the pharmaceutical industry. J Med Ethics 2006; 32(10): 559–563. DOI: https://doi.org/10.1136/jme.2005.014480
37. Roughhead EE, Harvey KJ, Gilbert AL. Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Aust N Z J Med 1998; 28(3): 306–310. DOI: https://doi.org/10.1111/j.1445-5994.1998.tb01953.x
38. Melfitt JJ. Key opinion leaders: where they come from and how that affects the drugs you prescribe. Dermatol Ther 2009; 22(3): 262–268. DOI: https://doi.org/10.1111/j.1529-8019.2009.01240.x
39. Sismondo S. How to make opinion leaders and influence people. CMAJ 2015; 187(10): 759–760. DOI: https://doi.org/10.1503/cmaj.150032
40. Lee A, Ayash O, Magancy A, et al. Key opinion leaders motivate increased prescriptions among their local. J Urol 2019; 201(Supplement 4): e628. DOI: https://doi.org/10.1097/01.ju.0000556246.28185.d5
41. Carroll AE, Vreeman RC, Buddenbaum J, Inui TS. To what extent do educational interventions impact medical trainees’ attitudes and behaviors regarding industry-trainee and industry-physician relationships? Pediatrics 2007; 120(6): e1528–e1535. DOI: https://doi.org/10.1542/peds.2007-0363
42. King M, Essick C, Bearman P, Ross JS. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. BMJ 2013; 346: f264. DOI: https://doi.org/10.1136/bmj.f264
43. McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA 2001; 286(16): 1994–1999. DOI: https://doi.org/10.1001/jama.286.16.1994
44. Epstein AJ, Busch SH, Busch AB, et al. Does exposure to conflict of interest policies in psychiatry residency affect antidepressant prescribing? Med Care 2013; 51(2): 199–203. DOI: https://doi.org/10.1097/MCLR.0b013e318277beb19
45. Alkhaleed L, Kahale L, Nass H, et al. Legislative, educational, policy and other interventions targeting physicians’ interaction with pharmaceutical companies: a systematic review. BMJ Open 2014; 4(7): e004880. DOI: https://doi.org/10.1136/bmjopen-2014-004880
46. Haute Autorité De Sante. [Medical Visit Charter: Implementation of the Certification Procedure – First Assessment] Chartre De La Visite Medicale: Mise En Oeuvre De La Procedure De Certification – Premier Bilan (in French). 2009; https://www.has-sante.fr/upload/docs/application/pdf/2009-11/premier_bilan_certif_vm_112009.pdf (accessed 24 Aug 2021).
47. De forskande lakemedelsforetagena. [Open reporting of value transfers] Öppen rapportering av värdeväxlingar (in Swedish). 2015; https://www.lif.se/etik/oppen-rapportering-av-vardeoverforingar/ (accessed 24 Aug 2021).
48. Oregon Academy of Family Physicians. About OAFP; https://oafp.org/about/ (accessed 24 Aug 2021).
49. The Ontario College of Family Physicians. Feedback on Physicians’ Relationships with Industry: Practice, Education and Research. 2014; http://policyconsult.cpsno.on.ca/wp-content/uploads/2014/05/Ontario-College-of-Family-Physicians.pdf (accessed 24 Aug 2021).
50. College of Psychiatrists of Ireland. The Relationship between Psychiatrists, the College of Psychiatrists of Ireland and the Pharmaceutical Industry. 2013; https://www.irishpsychiatry.ie/wp-content/uploads/2017/04/CPsych-Position-Paper-Psychiatrists-relationship-with-Pharmaceutical-Companies-20-03-13.pdf (accessed 24 Aug 2021).
51. Zetterqvist AV, Merlo J, Mulini S. Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation. PLoS Med 2015; 12(2): e1001785. DOI: https://doi.org/10.1371/journal.pmed.1001785

52. Fischer MA, Keough ME, Baril JL, et al. Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med 2009; 24(7): 795–801. DOI: https://doi.org/10.1007/s11606-009-0989-6

53. Spithoff S. Industry involvement in continuing medical education: time to say no. Can Fam Physician 2014; 60(8): 694–696.

54. O’Brien MA, Rogers S, Jamtvedt G, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2007; 308(8): CD000409. DOI: https://doi.org/10.1002/14651858.CD000409.pub2

55. O’Connell C. Pressure mounts to strip industry funding from continuing medical education programs. CMAJ 2010; 182(17): E775–E776. DOI: https://doi.org/10.1503/cmaj.109-3693

56. Steinbrook R. Financial support of continuing medical education. JAMA 2008; 299(9): 1060–1062. DOI: https://doi.org/10.1001/jama.299.9.1060